NEW YORK (GenomeWeb News) – Advanced Cell Diagnostics said Tuesday that it has raised $5.4 million in a Series A financing from Morningside Ventures.

The company plans to use the funding to develop diagnostic tests based on its RNAscope technology.

The RNAscope is a multiplex fluorescent and chromogenic in situ hybridization platform used to detect and quantify RNA biomarkers. ACD partners with pharmaceutical and biotechnology companies to validate biomarkers for targeted therapeutic development in cancer and other diseases.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.